Physician profile
Robert C Gordon
NPI 1538168331
$1,995.89
in general payments reported to CMS, 2019-2025
21 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $102 · 2021: $270 · 2022: $376 · 2023: $351 · 2024: $345 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.47 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.72 | 2019-2025 | |
| Exact Sciences Corporation | $351.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $180.83 | 2023-2025 | Veozah |
| Ge Healthcare | $165.58 | 2023 | |
| Axonics, INC. | $141.23 | 2022 | |
| Coopersurgical, INC. | $106.47 | 2021-2024 | Paragard T 380a, Summit Doppler, Paragard T 380a |
| Aspira Women'S Health INC | $60.85 | 2019-2020 | |
| Hologic Sales and Service, LLC | $59.03 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $57.69 | 2020-2022 | |
| Millicent US INC | $53.75 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Mayne Pharma Commercial LLC | $47.90 | 2023-2024 | |
| Therapeuticsmd, INC. | $45.35 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $44.47 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $42.30 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $33.98 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $30.63 | 2021 | |
| Biogen, INC. | $27.37 | 2024 | Zurzuvae |
| Organon LLC | $25.99 | 2024 | |
| Sumitomo Pharma America, INC. | $23.74 | 2023 | Myfembree |
| Pfizer INC. | $12.64 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.